TF
RNAM

Trek Financial’s Avidity Biosciences RNAM Stock Holding History

Trek Financial’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-71,541
Closed -$2.92M – 443
2024
Q2 		$2.92M Buy
+71,541
New +$2.05M 0.23% 110

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trek Financial's RNAM Position: Q3 2024 in Review

Trek Financial sold out of Avidity Biosciences (RNAM) in Q3 2024, closing a stake of 71,541 shares — an estimated $2.92M sold.

Trek Financial first reported a position in RNAM in Q2 2024 and held it in 1 quarter. The position peaked at $2.92M in Q2 2024. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

  • Trek Financial reported no remaining Avidity Biosciences position as of Q3 2024 after selling out during the quarter.
  • Trek Financial sold 71,541 Avidity Biosciences shares in Q3 2024, an estimated $2.92M.
  • Trek Financial first reported a position in Avidity Biosciences in Q2 2024 and held it in 1 quarter.
  • Trek Financial's Avidity Biosciences position peaked at $2.92M in Q2 2024.
  • 245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on Trek Financial's 13F filing for Q3 2024, filed 14 Nov 2024.